166 related articles for article (PubMed ID: 7776837)
21. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
[TBL] [Abstract][Full Text] [Related]
22. A prospective assessment of chemotherapy-related nausea and vomiting in children with cancer.
Zeltzer LK; LeBaron S; Zeltzer PM
Am J Pediatr Hematol Oncol; 1984; 6(1):5-16. PubMed ID: 6711763
[TBL] [Abstract][Full Text] [Related]
23. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
24. [Pediatric oncology: results and future therapeutic perspectives].
Paolucci G; Vecchi V; Burnelli R; Facchini E; Civino A; Pericoli R; Borghetti A
Minerva Pediatr; 1993 Sep; 45(9):325-39. PubMed ID: 8302228
[No Abstract] [Full Text] [Related]
25. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy.
Relling MV; Mulhern RK; Fairclough D; Baker D; Pui CH
J Pediatr; 1993 Nov; 123(5):811-6. PubMed ID: 8229497
[TBL] [Abstract][Full Text] [Related]
26. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.
Dow GJ; Meyers FH
J Clin Pharmacol; 1981; 21(S1):128S-132S. PubMed ID: 6271818
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
28. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Dick GS; Meller ST; Pinkerton CR
Arch Dis Child; 1995 Sep; 73(3):243-5. PubMed ID: 7492164
[TBL] [Abstract][Full Text] [Related]
29. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid.
Feigenbaum JJ; Richmond SA; Weissman Y; Mechoulam R
Eur J Pharmacol; 1989 Oct; 169(1):159-65. PubMed ID: 2557222
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use.
Rosenthal J; Howell M; Earl V; Malik M
Am J Med; 2021 Dec; 134(12):e582-e583. PubMed ID: 34343506
[No Abstract] [Full Text] [Related]
32. [Antiemetic protocol in oncohematologic polychemotherapy].
Bianconcini G; Mazzali F; Morini A; Gobbi F
Minerva Med; 1988 May; 79(5):379-86. PubMed ID: 3374828
[TBL] [Abstract][Full Text] [Related]
33. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
34. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
[TBL] [Abstract][Full Text] [Related]
35. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine.
Ungerleider JT; Andrysiak T; Fairbanks L; Goodnight J; Sarna G; Jamison K
Cancer; 1982 Aug; 50(4):636-45. PubMed ID: 6284334
[TBL] [Abstract][Full Text] [Related]
36. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
37. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.
Cocchetto DM; Cook LF; Cato AE
Drug Intell Clin Pharm; 1981 Nov; 15(11):867-75. PubMed ID: 6271519
[TBL] [Abstract][Full Text] [Related]
38. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
39. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
40. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study.
Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L
J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
